

HR 413

To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.

Congress: 113 (2013–2015, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 23, 2013

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Feb 8, 2013)

Official Text: <https://www.congress.gov/bill/113th-congress/house-bill/413>

Sponsor

Name: Rep. Welch, Peter [D-VT-At Large]

Party: Democratic • **State:** VT • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Braley, Bruce L. [D-IA-1]	D · IA		Jan 23, 2013
Rep. Cooper, Jim [D-TN-5]	D · TN		Jan 23, 2013
Rep. Hanna, Richard L. [R-NY-22]	R · NY		Jan 23, 2013

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jan 25, 2013
Ways and Means Committee	House	Referred to	Feb 8, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jan 23, 2013)

Amends the American Taxpayer Relief Act of 2012 to eliminate the two-year delay (until January 1, 2016) of the authority of the Secretary of Health and Human Services (HHS) to implement oral-only End Stage Renal Disease (ESRD)-related drugs in the ESRD prospective payment system (PPS) under title XVIII (Medicare) of the Social Security Act. (Thus authorizes the Secretary to implement such drugs in the ESRD-PPS immediately.)

Actions Timeline

- **Feb 8, 2013:** Referred to the Subcommittee on Health.
- **Jan 25, 2013:** Referred to the Subcommittee on Health.
- **Jan 23, 2013:** Introduced in House
- **Jan 23, 2013:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.